Logo image of ABVX.PA

ABIVAX SA (ABVX.PA) Stock Fundamental Analysis

EPA:ABVX - Euronext Paris - Matif - FR0012333284 - Common Stock - Currency: EUR

7.35  -0.33 (-4.3%)

Fundamental Rating

2

ABVX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. ABVX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ABVX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ABVX has reported negative net income.
ABVX had a negative operating cash flow in the past year.
ABVX had negative earnings in each of the past 5 years.
In the past 5 years ABVX always reported negative operating cash flow.
ABVX.PA Yearly Net Income VS EBIT VS OCF VS FCFABVX.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M

1.2 Ratios

ABVX's Return On Assets of -62.37% is on the low side compared to the rest of the industry. ABVX is outperformed by 65.28% of its industry peers.
ABVX's Return On Equity of -140.29% is on the low side compared to the rest of the industry. ABVX is outperformed by 62.50% of its industry peers.
Industry RankSector Rank
ROA -62.37%
ROE -140.29%
ROIC N/A
ROA(3y)-58.35%
ROA(5y)-57.39%
ROE(3y)-396.68%
ROE(5y)-451.03%
ROIC(3y)N/A
ROIC(5y)N/A
ABVX.PA Yearly ROA, ROE, ROICABVX.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABVX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABVX.PA Yearly Profit, Operating, Gross MarginsABVX.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

ABVX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ABVX has been increased compared to 5 years ago.
The debt/assets ratio for ABVX has been reduced compared to a year ago.
ABVX.PA Yearly Shares OutstandingABVX.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
ABVX.PA Yearly Total Debt VS Total AssetsABVX.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

ABVX has an Altman-Z score of -1.25. This is a bad value and indicates that ABVX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ABVX (-1.25) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.48 indicates that ABVX is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.48, ABVX is in line with its industry, outperforming 52.78% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Altman-Z -1.25
ROIC/WACCN/A
WACCN/A
ABVX.PA Yearly LT Debt VS Equity VS FCFABVX.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

2.3 Liquidity

ABVX has a Current Ratio of 3.04. This indicates that ABVX is financially healthy and has no problem in meeting its short term obligations.
ABVX's Current ratio of 3.04 is fine compared to the rest of the industry. ABVX outperforms 66.67% of its industry peers.
A Quick Ratio of 3.04 indicates that ABVX has no problem at all paying its short term obligations.
ABVX has a better Quick ratio (3.04) than 68.06% of its industry peers.
Industry RankSector Rank
Current Ratio 3.04
Quick Ratio 3.04
ABVX.PA Yearly Current Assets VS Current LiabilitesABVX.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ABVX have decreased strongly by -10.50% in the last year.
EPS 1Y (TTM)-10.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ABVX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.23% yearly.
Based on estimates for the next years, ABVX will show a very strong growth in Revenue. The Revenue will grow by 222.28% on average per year.
EPS Next Y-6.86%
EPS Next 2Y1.09%
EPS Next 3Y-5.76%
EPS Next 5Y26.23%
Revenue Next Year628.34%
Revenue Next 2Y691.33%
Revenue Next 3Y99.78%
Revenue Next 5Y222.28%

3.3 Evolution

ABVX.PA Yearly Revenue VS EstimatesABVX.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
ABVX.PA Yearly EPS VS EstimatesABVX.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABVX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABVX.PA Price Earnings VS Forward Price EarningsABVX.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABVX.PA Per share dataABVX.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A cheap valuation may be justified as ABVX's earnings are expected to decrease with -5.76% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.09%
EPS Next 3Y-5.76%

More info and screens

0

5. Dividend

5.1 Amount

ABVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIVAX SA

EPA:ABVX (3/7/2025, 7:00:00 PM)

7.35

-0.33 (-4.3%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07
Earnings (Next)03-24 2025-03-24/amc
Inst Owners41.83%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap465.87M
Analysts86.67
Price Target28.46 (287.21%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)14.06%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-1.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.68
P/tB 4.59
EV/EBITDA N/A
EPS(TTM)-3.2
EYN/A
EPS(NY)-2.43
Fwd EYN/A
FCF(TTM)-2.45
FCFYN/A
OCF(TTM)-2.44
OCFYN/A
SpS0
BVpS2
TBVpS1.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -62.37%
ROE -140.29%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.35%
ROA(5y)-57.39%
ROE(3y)-396.68%
ROE(5y)-451.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 37.15%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.04
Quick Ratio 3.04
Altman-Z -1.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1885.45%
Cap/Depr(5y)1638.64%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.52%
EPS Next Y-6.86%
EPS Next 2Y1.09%
EPS Next 3Y-5.76%
EPS Next 5Y26.23%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year628.34%
Revenue Next 2Y691.33%
Revenue Next 3Y99.78%
Revenue Next 5Y222.28%
EBIT growth 1Y-143.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-35.09%
EBIT Next 3Y-29.64%
EBIT Next 5Y36.74%
FCF growth 1Y-226.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-225.29%
OCF growth 3YN/A
OCF growth 5YN/A